Sarepta Therapeutics (MEX:SRPT) Cyclically Adjusted Revenue per Share: MXN190.11 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:SRPT Sarepta Therapeutics Inc MEX:SRPT
36 GF Score
Price MXN306.00
GF Value MXN1,592.40
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Sarepta Therapeutics Cyclically Adjusted Revenue per Share?

Sarepta Therapeutics MEX:SRPT 36 Cyclically Adjusted Revenue per Share is MXN190.11 as of Jun. 2026. GuruFocus rates MEX:SRPT with a GF Score™ of 36/100 and a GF Value™ of MXN1,592.40 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Sarepta Therapeutics's adjusted revenue per share for the three months ended in Jun. 2026 was MXN66.408. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN190.11 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Sarepta Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 13.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 28.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 30.80% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 26.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Sarepta Therapeutics was 32.80% per year. The lowest was 2.40% per year. And the median was 21.50% per year.

As of today (2026-09-09), Sarepta Therapeutics's current stock price is MXN306.00. Sarepta Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN190.11. Sarepta Therapeutics's Cyclically Adjusted PS Ratio of today is 1.61.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sarepta Therapeutics was 98.48. The lowest was 1.17. And the median was 23.76.


Sarepta Therapeutics  (MEX:SRPT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sarepta Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=306.00/190.11
=1.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sarepta Therapeutics was 98.48. The lowest was 1.17. And the median was 23.76.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Sarepta Therapeutics Cyclically Adjusted Revenue per Share Related Terms


Sarepta Therapeutics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Sarepta Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics Cyclically Adjusted Revenue per Share Chart

Sarepta Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 199.15

Sarepta Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 204.20 190.52 199.15 188.60 190.11

MEX:SRPT vs AUPH, PVLA, MLYS: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Sarepta Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sarepta Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's Cyclically Adjusted PS Ratio falls into.


MEX:SRPT
36GF Score
Sarepta Therapeutics Inc MEX:SRPT
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sarepta Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sarepta Therapeutics's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=66.408/333.9520*333.9520
=66.408

Current CPI (Jun. 2026) = 333.9520.

Sarepta Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.000 241.428 0.000
201612 2.045 241.432 2.829
201703 5.494 243.801 7.526
201706 11.512 244.955 15.695
201709 13.554 246.819 18.339
201712 17.639 246.524 23.895
201803 18.160 249.554 24.302
201806 22.064 251.989 29.241
201809 22.173 252.439 29.333
201812 24.148 251.233 32.099
201903 23.530 254.202 30.912
201906 24.588 256.143 32.057
201909 26.359 256.759 34.284
201912 25.322 256.974 32.907
202003 34.873 258.115 45.119
202006 40.666 257.797 52.679
202009 40.502 260.280 51.966
202012 36.586 260.474 46.907
202103 37.801 264.877 47.659
202106 40.959 271.696 50.344
202109 48.755 274.310 59.356
202112 48.076 278.802 57.586
202203 48.111 287.504 55.884
202206 53.677 296.311 60.496
202209 52.858 296.808 59.473
202212 57.357 296.797 64.537
202303 51.815 301.836 57.328
202306 50.468 305.109 55.239
202309 65.024 307.789 70.551
202312 64.907 306.746 70.664
202403 69.233 312.332 74.025
202406 67.063 314.175 71.285
202409 91.577 315.301 96.994
202412 103.413 315.605 109.425
202503 156.513 319.799 163.440
202506 107.916 322.561 111.727
202509 73.085 324.800 75.144
202512 76.068 324.054 78.391
202603 108.094 330.213 109.318
202606 66.408 333.952 66.408

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN190.11 mean?
Sarepta Therapeutics (MEX:SRPT) has a Cyclically Adjusted Revenue per Share of MXN190.11 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sarepta Therapeutics and its competitors.
Is Sarepta Therapeutics' Cyclically Adjusted Revenue per Share too high?
Sarepta Therapeutics' current Cyclically Adjusted Revenue per Share is MXN190.11. Overall, Sarepta Therapeutics has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Cyclically Adjusted Revenue per Share compare to AUPH and PVLA?
Sarepta Therapeutics' Cyclically Adjusted Revenue per Share of MXN190.11 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sarepta Therapeutics and its competitors. Sarepta Therapeutics's current Cyclically Adjusted Revenue per Share is MXN190.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (MEX:SRPT) is currently considered Possible Value Trap. The stock's GF Value™ is MXN1,592.40, compared to a current price of MXN306.00 — trading 80.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN190.11. Sarepta Therapeutics' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Sarepta Therapeutics (MEX:SRPT), the current Cyclically Adjusted Revenue per Share is MXN190.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sarepta Therapeutics (MEX:SRPT) Overvalued in 2026?

Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued. The current stock price of MXN306.00 is trading 80.8% below its estimated GF Value™ of MXN1,592.40. GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.

Key valuation signals for MEX:SRPT:

  • Cyclically Adjusted Revenue per Share: MXN190.11
  • GF Value™: MXN1,592.40 vs. price of MXN306.00 (80.8% below fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the MEX:SRPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sarepta Therapeutics Business Description

Address 215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
36GF Score

Get the complete analysis for MEX:SRPT

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN306.00
Price
MXN1,592.40
GF Value